The medical sector is an ever-evolving system of healing that consistently brings new methods to the forefront, discards inefficient practices and reintroduces methods of healing from our past.

 

Trending: adjective/

a general direction in which something is developing or changing.

 

All investors want to “get in” at the beginning of a trend so they can reap significant gains when the stock gains traction and takes off.

 

Trending sectors don’t always seem to be feasible. We see companies offering products or services on a fledgling basis and our instinct seems to be “that will never take off.”

 

We found a trend in the biopharma sector. What? You may be thinking “biopharma company shares go up when there are discoveries, breakthroughs, innovation and FDA catalysts…not trends.

 

We all wish we could have gotten shares in Amazon, Vertex Pharmaceuticals, Apple, Facebook or any number of trending success stories with shares that were once available at a low price. Yet we did not.

 

We hope you are at this page because you are a savvy investor, looking for an opportunity to acquire shares in a trending sector. Are you the kind of investor who wants to double, triple or even quadruple your investment in a short amount of time?

 

The success in today’s medicine come at a furious pace as science and technology advance rapidly. The mapping of the human genome in 2000 created an entire sector of medicine never imaginable. In the early 2000s this sector of medicine was trending and those who invested in those early days reaped significant rewards. In hindsight this was a trend.

 

Of course, all sectors of the investment marketplace have their trending moments. Personal computers were a trend in the 1970’s bought and used by people fascinated with their potential. Then, in the 1980’s, Bill Gates and Steve Jobs came along.

 

One of today’s medical trends is the gravitation toward traditional medicines like herbs, leeches, cannabis, and many other compounds made from natural earth substances. Some of these long-abandoned treatments are being reintroduced.

 

Only now, they can be used in conjunction with modern medical practices with the progressive thought that modern medicine is more effective in fighting a specific problem, but the traditional medicine works better to keep the body in balance on a daily basis.

 

We would like to introduce you to a new trend in traditional medicine coupled with the technology available to us today and the company bringing it to market.

 

THE PSYCHEDELIC MEDICAL INDUSTRY

 

From LSD and magic mushrooms, to Ecstasy (MDMA) and other hallucinogenic compounds, the medical community is taking a fresh look at these traditional healing practices with a 21st century eye.

 

EHAVE, Inc. is involved in data driven treatment tools for brain disorders, diseases and more recently, they’ve become involved with Psychedelic Medicine. The company is based in Toronto, Canada and their shares are traded on the OTC Markets under the ticker symbol (EHVVF).

 

We think the psychedelic medicine industry is going to take the market by storm.  The choices for investment are few right now so it’s pretty much like shooting fish in a barrel. We believe EHAVE shares offer the best opportunity for significant future gains and we will discuss the reasons below.

 

Earlier this year, EHAVE acquired 100% of PsychedeliTech (PsyTech), a division of Tel Aviv, Israel based Israel Cannabis Limited. Psytech will sponsor an annual summit, initiated this year, to advance the use of psychedelics as a medicine.

 

Speakers for the 2020 PsyTech Summit include some of the world’s foremost experts in the psychedelic medicine field and high-profile personalities. Christian Angermayer, Founder of ATAI Life Sciences, Rick Doblin, Ph.D., Executive Director of Multidisciplinary Association for Psychedelic Studies (MAPS), Bruce Linton, Founder, and Former Chairman and Co-CEO of Canopy Growth Corporation, Dr. Rosalind Watts, Clinical Psychologist at the Psychedelic Research Group At Imperial College London, and JR Rahn, Founder & Co-CEO of MindMed are just some of the speakers at PsyTech.

 

The acquisition of PsychedeliTech and the initiation of the PsyTech summit places EVAVE at the forefront of expertise in the field of psychedelic medicine. It’s a big factor in separating EHAVE from other companies trying to enter the sector.

IndustryNews.Tips

Ever Wish You Were Aware of a Hot New Sector Before It Experiences Explosive Growth?

Industry News Special Report  "The Next Hot Market Sector"

The medical sector is an ever-evolving system of healing that consistently brings new methods to the forefront, discards inefficient practices and reintroduces methods of healing from our past.

When Cannabis stocks started "trending" we saw moves in companies stock like Cronos Group (NASDAQ: CRON) of over 8000% running from .27/share in 2016 to nearly $22/share in 2019. A $1000 investment back then became worth over $81,000 at it's recent peak in just 3 years time!

We believe we have identified a sector and perhaps a stock within that sector, could realize this type of exponential growth.

 

Trending: adjective/

a general direction in which something is developing or changing.

 

All investors want to “get in” at the beginning of a trend so they can reap significant gains when the stock gains traction and takes off.

 

Trending sectors don’t always seem to be feasible. We see companies offering products or services on a fledgling basis and our instinct seems to be “that will never take off.”

 

We found a trend in the biopharma sector. What? You may be thinking “biopharma company shares go up when there are discoveries, breakthroughs, innovation and FDA catalysts…not trends.

 

We all wish we could have gotten shares in Amazon, Vertex Pharmaceuticals, Apple, Facebook or any number of trending success stories with shares that were once available at a low price. Yet we did not.

 

We hope you are at this page because you are a savvy investor, looking for an opportunity to acquire shares in a trending sector. Are you the kind of investor who wants to double, triple or even quadruple your investment in a short amount of time?

 

The success in today’s medicine come at a furious pace as science and technology advance rapidly. The mapping of the human genome in 2000 created an entire sector of medicine never imaginable. In the early 2000s this sector of medicine was trending and those who invested in those early days reaped significant rewards. In hindsight this was a trend.

 

Of course, all sectors of the investment marketplace have their trending moments. Personal computers were a trend in the 1970’s bought and used by people fascinated with their potential. Then, in the 1980’s, Bill Gates and Steve Jobs came along.

 

One of today’s medical trends is the gravitation toward traditional medicines like herbs, leeches, cannabis, and many other compounds made from natural earth substances. Some of these long-abandoned treatments are being reintroduced.

 

Only now, they can be used in conjunction with modern medical practices with the progressive thought that modern medicine is more effective in fighting a specific problem, but the traditional medicine works better to keep the body in balance on a daily basis.

 

We would like to introduce you to a new trend in traditional medicine coupled with the technology available to us today and the company bringing it to market.

 

THE PSYCHEDELIC MEDICAL INDUSTRY

 

From LSD and magic mushrooms, to Ecstasy (MDMA) and other hallucinogenic compounds, the medical community is taking a fresh look at these traditional healing practices with a 21st century eye.

 

EHAVE, Inc. is involved in data driven treatment tools for brain disorders, diseases and more recently, they’ve become involved with Psychedelic Medicine. The company is based in Toronto, Canada and their shares are traded on the OTC Markets under the ticker symbol (OTC: EHVVF).

 

We think the psychedelic medicine industry is going to take the market by storm.  The choices for investment are few right now so it’s pretty much like shooting fish in a barrel. We believe EHAVE shares offer the best opportunity for significant future gains and we will discuss the reasons below.

Key Recent Acquisition

 

Earlier this year, EHAVE acquired 100% of PsychedeliTech (PsyTech), a division of Tel Aviv, Israel based Israel Cannabis Limited. Psytech will sponsor an annual summit, initiated this year, to advance the use of psychedelics as a medicine.

 

Speakers for the 2020 PsyTech Summit include some of the world’s foremost experts in the psychedelic medicine field and high-profile personalities. Christian Angermayer, Founder of ATAI Life Sciences, Rick Doblin, Ph.D., Executive Director of Multidisciplinary Association for Psychedelic Studies (MAPS), Bruce Linton, Founder, and Former Chairman and Co-CEO of Canopy Growth Corporation, Dr. Rosalind Watts, Clinical Psychologist at the Psychedelic Research Group At Imperial College London, and JR Rahn, Founder & Co-CEO of MindMed are just some of the speakers at PsyTech.

 

The acquisition of PsychedeliTech and the initiation of the PsyTech summit places EHAVE at the forefront of expertise in the field of psychedelic medicine. It’s a big factor in separating EHAVE from other companies trying to enter the sector.

Mycotopia Therapy is a new, wholly owned subsidiary of Ehave, Inc. Mycotopia Therapy offers a new paradigm for mental wellness. They provide a human experience of building a roadmap of optimal mind-body-spirit health. Their doctors and practitioners are on the cusp of a new paradigm for healing your brain and mindful of how your mental wellness will follow.

 

Mycotopia Therapy was founded on the principles of Ehave, Inc. Cutting edge technology meets updated psychiatric paradigms using the top practitioners in the industry of evidence-based neuroscience.

 

They are building and partnering to provide a worldwide network of clinics and wellness centers. These centers will be focused on natural and digital therapies to heal mental wellness issues. Mycotopia Therapy was launched to offer solutions to mental wellness. Psychedelic therapy offers a science-based approach to address the expanding mental health crisis.

 

 

 

EHAVE has now become a company with two distinct operations. A software company with a platform to track data in patients being treated for ADHD and other brain disorders (more on that below) and a psychedelic medicine company.

 

Clinical trials on psychedelic therapies are now underway in some of North America’s most prestigious universities including Yale and John Hopkins.

 

Mycotopia will focus on mushrooms. Psilocybin is contained in mushrooms (aka magic mushrooms) a hallucinogenic known to many as a recreational and illegal drug.

There are over 100 species of psilocybin-containing mushrooms with varying potencies, said Matthew Johnson, an associate professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore who studies psychedelic drugs such as psilocybin.

 

“And you just had some kind of mushroom…remember what the dormouse said, feed your head, feed your head” – Grace Slick

 

Once it enters the body, psilocybin is broken down into psilocin, a substance that acts like the neurotransmitter serotonin, which regulates mood. Psilocybin is known to activate a specific type of serotonin receptor in the brain that triggers its psychedelic effects, Johnson said.

 

There are 58 books available on Amazon that discuss the medicinal value of psychedelics.

 

The Beckley Foundation, based in the UK, has been researching psychedelics since 1998. They have done extensive research on psilocybin and the link we’ve provided below will connect you to their research page including 12 papers written on the subject: https://beckleyfoundation.org/science/substances-methods/psilocybin/

 

Beckley data on the impact of psilocybin on depression:

Additional information on Mycotopia Therapy can be found on the Company’s website at https://www.mycotopiatherapy.com

 

Psilocybin has received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA) in 2018 after evidence showed it may be more beneficial than current treatments for major depressive disorder (MDD). According to the World Health Organization, more than 40 million people in the U.S., and 450 million people worldwide, are dealing with a mental health condition.

 

“Psilocybin-assisted therapy can make life better for individuals suffering from mental health disorders such as anxiety, addiction, PTSD, OCD, and depression,” said Ehave, Inc. CEO Benjamin Kaplan. “We believe Psilocybin will be the next frontier for the cannabis industry and our Ehave Infinity Portal can easily be customized to deliver evidence-based therapeutic interventions to both patients and researchers.”

Researcher Rick Doblin has spent the past three decades studying the science of psychedelics. He explains, in the Ted Talk linked below, how drugs like LSD, psilocybin and MDMA affect your brain -- and shows how, when paired with psychotherapy, they could change the way we treat PTSD, depression, substance abuse and more.

Rick Doblin: https://www.youtube.com/watch?v=Q9XD8yRPxc8

 

In March the company announced that Dr. Mark Braunstein, DO, ABPN was appointed to its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics.

Dr. Mark Braunstein, “Dr. B,” is a whole health psychiatrist. He completed his residency in general psychiatry and his fellowship in child and adolescent psychiatry in 1997. Shortly thereafter, he began exploring the use of psychoactive plant-based medicines in the treatment of various psychiatric conditions in both children and adults. With over 22 years of clinical experience, Dr. B has pioneered a new path in psychiatric care that integrates wilderness programming, exercise, diet, spirituality, and natural medicines.

 

Dr. B is the medical director for multiple mental health clinics, including a groundbreaking psychedelic psychotherapy practice in Boulder, Colorado. His plant-based dosing protocols have made him a sought-after medical consultant, advisor, and educator. He runs inpatient and outpatient treatment programs focused on addiction treatment.

 

We’ve been talking about the Psychedelic Medicine “sector”, but does it really exist? Consider this headline from a recent financial publication:

 

Recent Headline from Bloomberg " The Psychedelics Bull Run Has Begun "

 

In the past, R&D on the medicinal benefits of hallucinogens was conducted primarily by NPOs. Only recently has the public company sector been created.

 

MindMed, an OTC Markets listed company, is undertaking clinical trials of medicines based on psychedelics.

 

Janssen Pharmaceuticals, a Belgian company owned by Johnson & Johnson, currently markets a keta - mine based nasal spray product called Spravato.

 

ATAI Life Sciences, based in Germany is developing a treatment based on ibogaine and noribogaine for the treatment of opioid use disorder.

 

The other EHAVE business:

Ehave is also developing software-based solutions for the digital management, assessment, and remediation of the most common mental health disorders faced by children and adolescents, with an initial focus on attention deficit hyperactivity disorder (ADHD). Ehave is launching several digital applications under its MegaTeam brand for the assessment and remediation of ADHD, with pilot studies underway at the Hospital for Sick Children (“SickKids”). Their main product is the Ehave Infinity Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights.

The company announced in early April it has entered a Multi-Tier Global Partnership with MyLifeID that will always allow individuals to carry their health and mental health records with them.

 

This partnership allows individuals to store their health and mental health history on the MyLifeID Pocket Cloud, which can be accessed by medical providers through Ehave’s dashboard. The data is stored on the MyLifeID Pocket Cloud in full compliance with the Health Insurance Portability and Accountability Act (HIPAA), and comes on the heels of the U.S. Department of Health and Human Services finalizing two transformative rules on March 9, 2020 giving patients unprecedented safe, secure access to their health and mental health data.

 

Why should only doctors, clinics and hospitals have access to an individual’s medical records? Why should it be an issue to obtain your medical records for a physician to review when you need it fast? Your medical records and history should belong to you, not held and coveted by the medical establishment that recorded your health data.

 

When patients, providers and payers have full access to health records, it opens more options for treatment and could eliminate many of the redundancies in the healthcare system.

 

 

 

The article linked here gives a clear picture of MyLifeID and the capabilities and benefits of its software. https://www.einpresswire.com/article/511112289/portable-mylifeid-is-ideal-for-travelers-and-those-in-the-industry

 

We like EHAVE. Inc. in these sectors for a few reasons.

  • They are initially working with a psilocybin derivative and psilocybin is a well know and well researched psychedelic compound.

 

  • The entry into EHAVE shares is easy right know with a lower market cap and affordable shares.

 

  • Ehave has its Infinity ID/MyLife ID partnership and the Mycotopia Therapy subsidiary to create multiple verticals.

 

Maybe you can see, like we do, the synergies between the EHAVE segments of treating patients with psilocybin and an ability to track, analyze and produce data to clinicians about the treatment. We believe the two segments complement each other and make EHAVE a unique player in Psychedelic Medicine.

 

EHAVE is a company experiencing growth and it’s happening at a rapid pace with a new partnership and a move into a new, progressive sector providing new opportunities for revenues.

Investment Highlights        EHave Inc. (OTC: EHVVF)

Recent Key Acquisition in the Psychedelics Sector

EHave Inc. has Announced Plans for Additional Acquisitions, Mergers or Joint Ventures

Recently restructured via reverse stock split (Tiny Float)

Recent Additions to the Board of Director's are Key Players

This Sector is Just Starting to Heat Up and is Likely to Experience Exponential Growth

EHave's PR is Becoming More Active

 

EHave Security Details

Market Cap: 8.9M

Shares Outstanding: 25.41M

Shares in the float: 14.61M

Held by insiders: 71.06%

Stay in informed on this Hot New Sector!

Enter your information below and we will keep you in loop on breaking news, research and more.

Your Friends at Industry News

EHave Inc. (OTC: EHVVF)

Receive Investor Relations Updates, Company News and Events Here

Enjoy the ride with us! 

Ehave Inc. (OTC: EHVVF) Sector News, Discussions and More at The Following Social Links.

  • LinkedIn
  • Facebook
  • Twitter

Privacy Policy and Disclaimer


Your Consent


By using our site, you consent to our online privacy policy and disclaimer.


Do we disclose any information to outside parties?


We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.


What information do we collect?


We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.


When registering on our site, as appropriate, you may be asked to enter your: e-mail address


What do we use your information for?


When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.


Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.


We send periodic emails


The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.


How do we protect your information?


We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.


Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.


Online Privacy Policy Only


This online privacy policy applies only to information collected through our website and not to information collected offline.

 

Contacting Us


If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.


Editor@TradersNewsSource.com


IndustryNews.Tips is a wholly owned subsidiary of Traders News Source and Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
 
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC's parent company has been compensated up to twenty thousand dollars cash via bank wire by erelations group for our coverage of ehvvf. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure. 

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
 

© 2020 IndustryNews.Tips